# Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

Study · id `cardio:ct-nct04169269` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04169269](<https://clinicaltrials.gov/study/NCT04169269>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04169269

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

## Technical summary

Registry record NCT04169269. Randomized; no masking; primary purpose prevention. Start 2020-01-13 (actual); primary completion 2020-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 128 participants (planned count; ClinicalTrials.gov record NCT04169269, source copy `cardio:ctgov-nct04169269-2020-01-18`, retrieved 2026-10-31)
- Started: 2020-01-13 (actual) (ClinicalTrials.gov record NCT04169269, source copy `cardio:ctgov-nct04169269-2020-01-18`, retrieved 2026-10-31)
- Primary completion: 2020-12 (anticipated) (ClinicalTrials.gov record NCT04169269, source copy `cardio:ctgov-nct04169269-2020-01-18`, retrieved 2026-10-31)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT04169269, source copy `cardio:ctgov-nct04169269-2020-01-18`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04169269, source copy `cardio:ctgov-nct04169269-2020-01-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04169269-2020-01-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
- Condition: Deep Vein Thrombosis
- Condition: Venous Thromboembolism
- Intervention (Drug): Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
- Intervention (Drug): Rivaroxaban 10 milligram Oral Tablet
- Lead sponsor: Florida Orthopaedic Institute
- Lead sponsor class: NETWORK
- Collaborator: Orthopaedic Trauma Association
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma (`cardio:pubmed-36399673`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d7af6e01ecb5062cc23b6bf32ff252c260bcf4432bbc66622d2a6e067c1fdc7c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
